Nervous System (e.g., Brain, Nerve, Etc.) Patents (Class 424/570)
-
Patent number: 5707657Abstract: A food supplement comprises isolated animal mesenchymal matter of fetal origin and extracts of animal organs of fetal origin, the mesenchymal matter consisting of a network of loose connective tissue and the food supplement being free of chemical preservatives.Type: GrantFiled: February 21, 1995Date of Patent: January 13, 1998Inventor: Raymond Bontemps
-
Patent number: 5690927Abstract: Human fetal neuro-derived cell lines are implanted into host tissues. The methods allow for treatment of a variety of neurological disorders and other diseases. A preferred cell line is SVG.Type: GrantFiled: June 2, 1995Date of Patent: November 25, 1997Assignee: The United States of America as represented by the Department of Health and Human ServicesInventors: Eugene O. Major, Carlo S. Tornatore, Kris Bankiewicz
-
Patent number: 5656267Abstract: This invention provides a method of alleviating chronic pain in humans. Viable, implantable cells are selected which release neuroactive substances that reduce chronic pain. The cells are cultured to improve their viability, and administered into a region of the central nervous system of a patient who is suffering from chronic pain. The cells continue to secrete the neuroactive substances within the patient without exogenous stimulation. Suitable implantable cells include adrenal medullary tissue cells, chromaffin cells or genetically engineered cells.Type: GrantFiled: January 27, 1995Date of Patent: August 12, 1997Inventors: Jacqueline Sagen, George Demetrios Pappas
-
Patent number: 5625040Abstract: A phosphacan proteoglycan molecule, or a functional derivatives thereof, binds to brain cells and to a number of cell adhesion molecules including Ng-CAM and N-CAM. Such proteoglycan molecules or functional derivatives, as well as nucleic acids coding therefore are useful in treating a subject having a disorder associated with conditions where it is desirable to promote nerve regeneration. The compositions and methods of the present invention are also useful for diagnosing and monitoring human tumors such as gliomas and astrocytomas.Type: GrantFiled: January 27, 1994Date of Patent: April 29, 1997Assignees: The Research Foundation of State University of New York, New York UniversityInventors: Richard U. Margolis, Renee K. Margolis, Patrice Maurel
-
Patent number: 5599560Abstract: Infusion of neurotrophins, preferably brain-derived neurotrophic factor, are shown to be effective agents for use in the alleviation of symptoms of depression, as demonstrated by reduction of "despair" in the animal forced swim test. Alterations in serotonin levels brought about by neurotrophins suggest use of these factors for the treatment of other disorders caused by defects in serotonin activity.Type: GrantFiled: November 10, 1994Date of Patent: February 4, 1997Assignee: Regeneron Pharmaceuticals, Inc.Inventor: Judith Siuciak
-
Patent number: 5560935Abstract: The present invention provides a physiologically active substance which inhibits plasma kallikrein production, improves peripheral blood flow, and exhibits analgesic, antiinflammatory and antiallergic action. The physiologically active substance of the present invention is prepared by activating various animals or animal tissues by means of inoculation with virus or tumor cells which act as a stressor, and then extracting the effective factor from the activated tissues. The substance exhibits a pharmacological action of inhibiting activity for production of plasma kallikrein and recovering and normalizing abnormal functions which are associated with the diseased state. The physiologically active substance and pharmaceutical compositions of the present invention exhibit excellent regulating activity for biofunctions. They provide recovery and normalization of abnormal functions in living organisms in various diseased states.Type: GrantFiled: September 27, 1994Date of Patent: October 1, 1996Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Jin-emon Konishi, Giichi Hamada
-
Patent number: 5556837Abstract: The present invention is broadly directed to treatment of an addictive disease or disorder. In particular, the invention relates to inhibiting or reversing the biochemical and neurophysiological changes that correlate with behavioral changes of addictive diseases or disorders. The method of the invention comprises administering to a subject suspected of suffering from an addictive disease or disorder an amount of brain-derived factor (BDNF) or neurotrophin-4 (NT-4), or both, effective to reverse behavioral changes that are associated with the addictive disease or disorder. In a specific Example, administration of BDNF or NT-4 inhibits or reverses increased expression of tyrosine hydroxylase and glial ibrillary acidic protein in the ventral tegmental area of the brain, and inhibits or reverses increased levels of cyclic-AMP-dependent protein kinase activity in the nucleus accumbens.Type: GrantFiled: August 1, 1994Date of Patent: September 17, 1996Assignees: Regeneron Pharmaceuticals Inc., Yale UniversityInventors: Eric J. Nestler, Melissa T. Berhow, Dana Beitner-Johnson, David S. Russell, Ronald M. Lindsay
-
Patent number: 5534615Abstract: Isolated CHF, isolated DNA encoding CHF, and recombinant or synthetic methods of preparing CHF are disclosed. These CHF molecules are shown to influence hypertrophic activity and neurological activity. Accordingly, these compounds or their antagonists may be used for treatment of heart failure, arrhythmic disorders, inotropic disorders, and neurological disorders.Type: GrantFiled: April 25, 1994Date of Patent: July 9, 1996Assignees: Genentech, Inc., The Regents of the University of CaliforniaInventors: Joffre Baker, Kenneth Chien, Kathleen King, Diane Pennice, William Wood
-
Patent number: 5532141Abstract: A method is taught whereby improved yields of lipid containing molecules, such as gangliosides, are obtained. Involved is the treatment of neural tissue from animals afflicted with GM1 gangliosidosis. Only members of the ovine family, e.g., sheep are so treated.Type: GrantFiled: June 13, 1995Date of Patent: July 2, 1996Inventor: Larry D. Holler
-
Patent number: 5529792Abstract: In order to isolate an inhibitor of the proliferation of endothelial cells from the tissue of vertebrates the tissue selected as the starting material e.g. embryonic tissue or adult brain tissue from birds or mammals, is centrifuged, homogenized and subsequently the tissue extract is applied to a cation exchanger and the substances which bind to the cation exchanger are subjected to a fractionation, the active fractions are separated by gel filtration chromatography and they are purified by reverse phase HPLC. The new inhibitor obtained in this way is suitable for treating disease states in which an inhibition of capillary growth is necessary such as for the treatment of tumors, rheumatoid arthritis, diabetic retinopathy and retrolental fibroplasia and for treating wounds in order to regulate the regeneration of blood vessels.Type: GrantFiled: November 10, 1993Date of Patent: June 25, 1996Assignee: Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.Inventors: Werner Risau, Hannes Drexler
-
Isolated components of dense microspheres derived from mammalian brain tissue and antibodies thereto
Patent number: 5525339Abstract: DMS present in the brain of individuals susceptible to cerebral amyloidosis disintegrate into DMS components to form cerebral amyloid plaques and other DMS components that are removed from the brain via circulating bodily fluids. Detecting the presence of these removed DMS components in circulating bodily fluids provides a diagnostic mechanism to determine the onset of cerebral amyloid plaque formation. Antibodies also can be raised against isolated DMS components and subsequently utilized in a diagnostic method capable of detecting the onset of cerebral amyloid plaque formation.Type: GrantFiled: December 17, 1993Date of Patent: June 11, 1996Assignee: DMS Pharmaceutical Inc.Inventor: Paul Averback -
Patent number: 5512304Abstract: A thromboplastin extract including an aqueous thromboplastin extract of a powdered thromboplastin source including a metal ion chelator. A thromboplastin reagent for use in blood coagulation tests, the thromboplastin reagent includes the extract and calcium ions, and may include one or more of a stabilizer and a preservative.A process for preparing a thromboplastin extract including extracting a powdered thromboplastin source in an aqueous solution having a metal ion chelator, and separating the powder in solution into sedimented powder and supernatant thromboplastin extract. The supernatant thromboplastin extract is mixed with calcium ions, and may be mixed with one or more of a stabilizer and a preservative, to prepare thromboplastin reagent.Type: GrantFiled: February 3, 1995Date of Patent: April 30, 1996Assignee: Helena Laboratories CorporationInventors: David A. Barrow, Richard L. Rullman
-
Patent number: 5484611Abstract: A method of producing docosahexaenoic acid and a method of treatment of animal bodies by administering the docosahexaenoic acid, the docosahexaenoic acid being linked to phospholipids which have been selectively purified from the brains of preferably 1-3 day old chicks.Type: GrantFiled: August 13, 1993Date of Patent: January 16, 1996Assignee: The Scottish Agricultural CollegeInventors: Raymond C. Noble, Massimo Cocchi
-
Patent number: 5391380Abstract: A thromboplastin extract including an aqueous thromboplastin extract of a powdered thromboplastin source including a metal ion chelator. A thromboplastin reagent for use in blood coagulation tests, the thromboplastin reagent includes the extract and calcium ions, and may include one or more of a stabilizer and a preservative.A process for preparing a thromboplastin extract including extracting a powdered thromboplastin source in an aqueous solution having a metal ion chelator, and separating the powder in solution into sedimented powder and supernatant thromboplastin extract. The supernatant thromboplastin extract is mixed with calcium ions, and may be mixed with one or more of a stabilizer and a preservative, to prepare thromboplastin reagent.Type: GrantFiled: May 14, 1993Date of Patent: February 21, 1995Assignee: Helena Laboratories, Corp.Inventors: David A. Barrow, Richard L. Rullman
-
Patent number: 5254350Abstract: A process for preparing a thromboplastin extract including extracting a powdered thromboplastin source in an aqueous solution having a metal ion chelator, and separating the powder in solution into sedimented powder and supernatant thromboplastin extract is disclosed. The supernatant thromboplastin extract is mixed with calcium ions, and may be mixed with one or more of a stabilizer and a preservative, to prepare thromboplastin reagent.Type: GrantFiled: July 22, 1991Date of Patent: October 19, 1993Assignee: Helena Laboratories CorporationInventors: David A. Barrow, Richard L. Rullman
-
Patent number: 5240714Abstract: A highly purified, Na.sup.+,K.sup.+ -ATPase inhibitory factor is disclosed herein. The factor does not cross-react with anti-digoxin antibody and exhibits uniquely characteristic UV absorbance maxima at approximately 202-210 nm and at 274-280 nm. The inhibitory factor has a molecular weight of less than 1000 Daltons, is non-peptidic, non-lipidic, and loses activity following charring or alkaline hydrolysis. The factor is useful as a pharmaceutical composition in methods for treating essential hypertension, cardiac malfunction and in regulating angiogenesis and active sodium transport and other conditions. Methods for purifying the factor from tissue and fluid extracts are also disclosed.Type: GrantFiled: August 29, 1989Date of Patent: August 31, 1993Inventor: Jose M. S. Rof
-
Patent number: 5202120Abstract: The present invention relates to "activated" immature astrocytes and the methods of utilizing the activated immature astrocytes as a means for promotingPursuant to the provisions of 35 U.S.C. .sctn.202(c), it is hereby acknowledged that the Government has certain rights in this invention, which was made in part with funds from the National Eye Institute of the National Institutes of Health.Type: GrantFiled: October 27, 1989Date of Patent: April 13, 1993Assignee: Case Western Reserve UniversityInventors: Jerry Silver, George M. Smith, James W. Jacobberger
-
Patent number: 5198216Abstract: A composition for enhancing the performance of animals, such as horses or dogs, is composed of adrenal and pituitary raw tissue concentrates, vitamin C, bioflavonoid complex, pantothenic acid, methionine, choline, vitamin B1, vitamin B2, vitamin B6, niacinamide, magnesium, vitamin B12, folic acid and organic iodine. The composition is adapted to be orally administered to an animal, is composed of all natural substances, and the relative proportions of the components are approximately:at least 40 parts adrenal raw tissue concentrate toat least 2 parts pituitary raw tissue concentrate to30-60 parts vitamin C to20-30 parts magnesium to10-20 parts of each of pantothenic acid, methionine and choline to8-15 parts of each of niacinamide and bioflavonoid complex to1-5 parts of each of vitamins B1, B2 and B6 to0.1-1 parts organic iodine to0.05-0.5 parts folic acid.Type: GrantFiled: July 30, 1990Date of Patent: March 30, 1993Assignee: Daliff CorporationInventor: David M. McGee
-
Patent number: 5104639Abstract: A method for establishing a treatment protocol for correcting an abnormal condition or disease in a living organism is described. The method comprises the steps of analyzing body fluids from normal and abnormal individuals to generate analysis patterns of the normal and abnormal fluids, comparing the patterns to determine differences in the patterns, and establishing a treatment protocol for the abnormal individual through chemical or metabolic therapy which treating will normalize the abnormal pattern.Type: GrantFiled: November 21, 1988Date of Patent: April 14, 1992Assignee: ESA, Inc.Inventor: Wayne R. Matson
-
Patent number: 5093317Abstract: Method of enhancing the survival of neuronal cells, more preferably non-mitotic neuronal cells and/or cholinergic cells in a mammal, which cells are at risk of dying, which method includes administering to the mammal an effective amount of a functional derivative of Insulin-like Growth Factor I or Insulin-like Growth Factor II.Type: GrantFiled: June 5, 1989Date of Patent: March 3, 1992Assignee: Cephalon, Inc.Inventors: Michael E. Lewis, James C. Kauer, Kevin R. Smith, Kathleen V. Callison, Frank Baldino, Jr.
-
Patent number: 5082670Type: GrantFiled: December 15, 1988Date of Patent: January 21, 1992Assignee: The Regents of the University of CaliforniaInventors: Fred H. Gage, Michael B. Rosenberg, Theodore Friedmann
-
Patent number: 5066496Abstract: Ganglioside mixtures and/or lipid mixtures e.g. from brain and omentum, are found to be effective to treat peptic ulcers.Type: GrantFiled: August 3, 1988Date of Patent: November 19, 1991Assignees: Angio-Medical Corporation, Trustees of Boston UniversityInventors: Sandor Szabo, Meryl S. A. Rubin, Michael Klibaner, Ahmad R. Kamarei, Robert S. Sinn, Nicholas Catsimpoolas
-
Patent number: 5057324Abstract: A physiologically active substance is extracted from infected tissues inoculated with a poxvirus. The novel substance of the present invention has inhibitory action against the formation of kallikrein, thus is useful as drugs such as antiinflammatory, analgesic and antiallergic agents.Type: GrantFiled: July 20, 1988Date of Patent: October 15, 1991Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventors: Yoji Shibayama, Yoshio Toyomaki
-
Patent number: 5017375Abstract: The present invention is based on the discovery that amyotrophic lateral sclerosis (ALS), Parkinson disease and Alzheimer disease are due to lack of a disorder-specific neurotrophic hormone or factor. Diagnosis is accomplished by assaying factors specific for a particular neuronal network or system; for example, dopamine neutotrophic hormones from striatum or caudate-putamen in the nigrostriatal dopaminergic neural system are used to diagnose and treat parkinsonism. With tissue culture, the presence or absence of spacific neurotrophic factos can be assessed in ALS, parkinsonism, and Alzheimer disease. If there is a deficiency, extracted and purified neurotrophic factors specific to the particular neuronal network or system can be injected into a patient having ALS, Alzheimer disease or parkinsonism for treatment of the disease.Type: GrantFiled: May 18, 1987Date of Patent: May 21, 1991Assignee: Baylor College of MedicineInventors: Stanley H. Appel, Yasuko Tomozawa
-
Patent number: 4985254Abstract: The present invention relates to physiologically active substances extracted from infected tissues inoculated with a poxvirus. The substances of the present invention have excellent actions to improve blood flow and recover functions of diseased tissues, thus are useful as drugs for various diseases caused by blood flow disorders.Type: GrantFiled: November 3, 1988Date of Patent: January 15, 1991Assignee: Nippon Zoki Pharmaceutical Co., Ltd.Inventor: Jin-emon Konishi
-
Patent number: 4981691Abstract: The invention provides novel improved oxygenated fluorocarbon nutrient solutions for treatment of hypoxic-ischemic neurologic tissue in mammals. The invention also provides methods of making such nutrient solution and methods of administering them.Type: GrantFiled: April 5, 1989Date of Patent: January 1, 1991Assignee: Thomas Jefferson UniversityInventors: Jewell L. Osterholm, Glenn D. Frazer
-
Patent number: 4980174Abstract: A novel method for alleviating depression comprises implanting monoamine producing living cells in the CNS of depressive subjects.Type: GrantFiled: December 23, 1988Date of Patent: December 25, 1990Inventors: Jacqueline Sagen, Caryl E. Sortwell, George D. Pappas
-
Patent number: 4957741Abstract: Lipid material or ganglioside from mammalian sources e.g. bovine and porcine brain or omentum is used to treat peptic ulcers.Type: GrantFiled: August 2, 1988Date of Patent: September 18, 1990Assignee: Angio-Medical Corp.Inventors: Ahmad R. Kamarei, Nicholas Catsimpoolas, Robert McCluer, Takashi Mise, Robert S. Sinn